Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway

Can Hu,Xin Zhang,Peng Song,Yu-Pei Yuan,Chun-Yan Kong,Hai-Ming Wu,Si-Chi Xu,Zhen-Guo Ma,Qi-Zhu Tang

DOI: https://doi.org/10.1016/j.redox.2020.101747

IF: 11.4

2020-10-01

Redox Biology

Abstract:<p>Meteorin-like (METRNL) protein is a newly identified myokine that functions to modulate energy expenditure and inflammation in adipose tissue. Herein, we aim to investigate the potential role and molecular basis of METRNL in doxorubicin (DOX)-induced cardiotoxicity. METRNL was found to be abundantly expressed in cardiac muscle under physiological conditions that was decreased upon DOX exposure. Cardiac-specific overexpression of METRNL by adeno-associated virus serotype 9 markedly improved oxidative stress, apoptosis, cardiac dysfunction and survival status in DOX-treated mice. Conversely, knocking down endogenous METRNL by an intramyocardial injection of adenovirus exacerbated DOX-induced cardiotoxicity and death. Meanwhile, METRNL overexpression attenuated, while METRNL silence promoted oxidative damage and apoptosis in DOX-treated H9C2 cells. Systemic METRNL depletion by a neutralizing antibody aggravated DOX-related cardiac injury and dysfunction in vivo, which were notably alleviated by METRNL overexpression within the cardiomyocytes. Besides, we detected robust METRNL secretion from isolated rodent hearts and cardiomyocytes, but to a less extent in those with DOX treatment. And the beneficial effects of METRNL in H9C2 cells disappeared after the incubation with a METRNL neutralizing antibody. Mechanistically, METRNL activated SIRT1 via the cAMP/PKA pathway, and its antioxidant and antiapoptotic capacities were blocked by SIRT1 deficiency. More importantly, METRNL did not affect the tumor-killing action of DOX in 4T1 breast cancer cells and tumor-bearing mice. Collectively, cardiac-derived METRNL activates SIRT1 via cAMP/PKA signaling axis in an autocrine manner, which ultimately improves DOX-elicited oxidative stress, apoptosis and cardiac dysfunction. Targeting METRNL may provide a novel therapeutic strategy for the prevention of DOX-associated cardiotoxicity.</p>

biochemistry & molecular biology

What problem does this paper attempt to address?

This paper aims to solve the serious cardiotoxicity problem caused by doxorubicin (DOX). DOX is a chemotherapeutic drug widely used in cancer treatment, but its clinical application is limited by cardiotoxicity, which may lead to left ventricular dysfunction and congestive heart failure. The paper studied the potential role of Meteorin - like (METRNL) protein in DOX - induced cardiotoxicity and its molecular mechanism. METRNL is a newly recognized myokine, which is known to regulate energy expenditure and inflammation in adipose tissue. The study found that METRNL is abundantly expressed under physiological conditions in cardiac muscle, but decreases after DOX exposure. By specifically overexpressing METRNL in the heart, the researchers observed significant improvements in oxidative stress, apoptosis, cardiac dysfunction, and survival status in DOX - treated mice. In addition, METRNL exerts antioxidant and anti - apoptotic effects by activating the cAMP/PKA/SIRT1 pathway, and this effect is blocked in the absence of SIRT1. The study also showed that METRNL does not affect the killing effect of DOX on 4T1 breast cancer cells and tumor - bearing mice. In conclusion, cardiac - derived METRNL activates the cAMP/PKA signaling axis in an autocrine manner, ultimately improving oxidative stress, apoptosis, and cardiac dysfunction caused by DOX. Targeting METRNL may provide a new therapeutic strategy for preventing DOX - related cardiotoxicity.